Deposition and Disposition of [C]Zanamivir Following Administration as an Intranasal Spray

This publication has 9 references indexed in Scilit:

• Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus Infections
  The Journal of Infectious Diseases, 1999
• Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
  Clinical Pharmacokinetics, 1999
• Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections
  New England Journal of Medicine, 1997
• Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography
  Clinical Pharmacology & Therapeutics, 1996
• Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza
  JAMA, 1996
• Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography*
  Clinical Pharmacology & Therapeutics, 1995
• 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
  Antimicrobial Agents and Chemotherapy, 1993
• Rational design of potent sialidase-based inhibitors of influenza virus replication
  Nature, 1993
• Performance Characteristics of an Eight-Ring Whole Body PET Scanner
  Journal of Computer Assisted Tomography, 1990